
News|Videos|September 29, 2025
Cemiplimab Plus Chemotherapy Versus Chemotherapy in Advanced NSCLC: 5-year Results from Phase 3 EMPOWER-Lung 3 Part 2 Trial
Author(s)Bruna Pellini, MD
Expert reviews favorable efficacy and durability 5-year results for cemiplimab plus chemotherapy versus chemotherapy in the EMPOWER-Lung 3 Part 2 trial.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced Melanoma
2
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
3
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
4
Dr Riedell on the Long-Term Efficacy of Tisa-Cel in R/R Follicular Lymphoma
5






































